A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis

Protocol No
NEURO-AMGEN-20230309
Staff Member
Ahmed Obeidat
Phase
III
Summary

This project is being done to determine if the study drug ABP 692 is similar to Ocrevus. ABP 692 will be compared to Ocrevus to see if it works as well, has similar side effects and is as well tolerated as Ocrevus .
Objective
ABP692 v Ocrelizumab in Relapsing-Remitting MS
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Multiple Sclerosis, Brain, Spinal Cord, and Nervous System